Skip to content
Bored Studies
RecruitingPhase 2

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

Cytokinetics · NCT06793371

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 40–85 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
60
US sites recruiting
24
Study start
February 6, 2025
Record last updated
August 27, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.

Being studied: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg); Placebo to match CK-4021586

Conditions: Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Males and females ≥ 40 years and ≤ 85 years of age at screening.
  • Diagnosed with HF with NYHA functional class II or III.
  • Screening echocardiography with LVEF ≥ 60%.
  • Screening NT-proBNP ≥ 300 pg/mL for participants in sinus rhythm and ≥ 900 pg/mL for participants with comorbid atrial fibrillation or flutter.
  • Body mass index \< 40 kg/m2.
  • Participants on beta-blockers, angiotensin-converting enzyme (ACE)/angiotensin II receptor blocker (ARB) or angiotensin receptor/neprilysin inhibitor (ARNI), must be on stable doses for more than 30 days prior to screening.
  • Participants on a glucagon-like peptide-1 (GLP-1) agonist must be on a stable dose for more than 24 weeks prior to screening with no anticipated plans to change dose during this study.

Exclusion Criteria

  • History or evidence of any other clinically significant disorder, malignancy, active infection, other condition, or disease that, in the opinion of the investigator or the Medical Monitor, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Recruiting US locations

Study contacts (from the official record)

  • Cytokinetics MD · 650-624-2929 · medicalaffairs@cytokinetics.com
All heart & blood pressure studies in Alabama →
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded… (NCT06793371) | Bored Studies